THERMOGENESIS HOLDINGS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6626 USD | +1.94% |
|
-19.20% | +10.25% |
| Apr. 16 | ThermoGenesis Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Apr. 10 | North American Morning Briefing : Traders Await -2- | DJ |
Financials (USD)
| Sales 2024 * | 16.86M | Sales 2025 * | 21.11M | Capitalization | 5.27M |
|---|---|---|---|---|---|
| Net income 2024 * | 2M | Net income 2025 * | 5M | EV / Sales 2024 * | 0.31 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.25 x |
| P/E ratio 2024 * |
8.28
x | P/E ratio 2025 * |
3.31
x | Employees | 41 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.89% |
More Fundamentals
* Assessed data
More news
Latest transcript on ThermoGenesis Holdings, Inc.
More press releases
| 1 day | +1.94% | ||
| 1 week | -19.20% | ||
| Current month | -7.20% | ||
| 1 month | -11.65% | ||
| 3 months | +79.08% | ||
| 6 months | -37.78% | ||
| Current year | +10.25% |
1 week
0.58
0.91
1 month
0.580.97
Current year
0.361.25
1 year
0.362.44
3 years
0.36142.20
5 years
0.36638.10
10 years
0.3619 710.02
| Managers | Title | Age | Since |
|---|---|---|---|
Xiao Chun Xu
CEO | Chief Executive Officer | 53 | 16-03-09 |
Jeffery Cauble
DFI | Director of Finance/CFO | 51 | 09-12-31 |
Wendy Samford
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Russell Medford
BRD | Director/Board Member | 69 | 17-02-23 |
Joseph Thomis
BRD | Director/Board Member | 78 | 17-01-09 |
Xiao Chun Xu
CEO | Chief Executive Officer | 53 | 16-03-09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.6626 | +1.94% | 8,586 |
| 24-04-18 | 0.65 | +3.17% | 20,823 |
| 24-04-17 | 0.63 | -10.14% | 35,801 |
| 24-04-16 | 0.7011 | -16.79% | 75,134 |
| 24-04-15 | 0.8426 | +2.76% | 11,622 |
Delayed Quote Nasdaq, April 19, 2024 at 04:30 pm EDT
More quotes
ThermoGenesis Holdings, Inc. develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. It provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and the CAR-TXpress platform for large scale cell manufacturing services. Its products include Clinical Bio-Banking Applications, Point-of-Care Applications and Large-Scale Cell Processing and Biomanufacturing. Its Clinical Bio-Banking Applications include AXP Automated Cell Separation System and BioArchive Automated Cryopreservation System. Its Point-of-Care Applications include PXP Point-of-Care System, PXP-LAVARE System and PXP-1000 System. Its Large-Scale Cell Processing and Biomanufacturing includes X-Series Products for general laboratory use and CAR-TXpress Platform for Clinical Manufacturing. AXP Automated Cell Separation System is an automated, fully closed cell separation system.
Sector
Office Equipment
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.6626
USD
Average target price
5
USD
Spread / Average Target
+654.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.25% | 5.17M | |
| +4.11% | 7.99B | |
| -13.04% | 2.77B | |
| +3.17% | 2.26B | |
| -30.67% | 1.1B | |
| -11.35% | 804M | |
| -19.61% | 739M | |
| -33.88% | 666M | |
| -57.88% | 658M | |
| -31.34% | 627M |
- Stock Market
- Equities
- THMO Stock
